Bristol Myers to merge scientific, clinical teams under new R&D structure

Impact · against what's priced in

BMY's R&D restructuring is a marginal positive as it aims to improve clinical integration and operational efficiency. However, structural changes are internal process improvements rather than immediate catalyst events for the pipeline.

BMY+0.10: No priced-in read yet
In context: Merging scientific and clinical teams is intended to streamline R&D, which may reduce friction in drug development cycles.
Read from the article alone

Bristol Myers to merge scientific, clinical teams under new R&D structure

r and dNew
biotech
BMY
clinical trials
pharma
restructuring

Top 1 mover · tap to explore

Bristol Myers to merge scientific, clinical teams under new R&D structure

How each ticker is affected

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

Bristol Myers to merge scientific, clinical teams under new R&D structure

How each ticker is affected

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

Track these names every morning.

iBio Targets First-Quarter Myostatin Data, Activin E Dosing as It Advances Obesity Pipeline

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development

Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho

FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track

Bristol Myers to merge scientific, clinical teams under new R&D structure

How each ticker is affected

Next reads from the same story arc

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

Bristol Myers to merge scientific, clinical teams under new R&D structure

How each ticker is affected

Next reads from the same story arc

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity

Track these names every morning.

iBio Targets First-Quarter Myostatin Data, Activin E Dosing as It Advances Obesity Pipeline

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development

Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho

FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track